Documented concern based on cited evidence — not a personalized safety check, not medical advice, and not a decision to combine or avoid. That decision belongs with your prescriber.

Low-grade concern — timing, disclosure, or lab context

Low-grade documented concern. Timing, disclosure, or a lab context decides whether it matters for you.

Mechanism and evidence

Chromium may modestly improve insulin sensitivity; on top of a GLP-1 agonist a small additional glucose-lowering effect is theoretically possible. The evidence base is weaker than for berberine.

Evidence tier: pharmacology-standard

The tier names the strongest cited study design. Some anchors studied the supplement on its own, or a related drug in the same class — in those pairs the grade rests on that evidence plus established pharmacology, as agreed with our medical reviewer.

What to discuss with your prescriber

  • Tell your prescriber you take chromium, especially if you have episodes of low blood sugar.
  • Do not treat chromium as a substitute for glucose monitoring.

← All reviewed pairs for GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide)